Tierney, Brend J. and McCann, Georgia A. and Cohn, David and Eisenhauer, Eric and Sudhakar, Meryl and Kuppusamy, Periannan and Hideg, Kálmán and Selvendrian, Karuppaiyah (2012) HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. Cancer Biology and Theraphy, 13 (9). pp. 766-775. ISSN 1538-4047, ESSN: 1555-8576
This is the latest version of this item.
|
Text
cbt.20559.pdf Download (1MB) | Preview |
Abstract
BRCA1 plays an important role in DNA damage and repair, homologous recombination, cell-cycle regulation and apoptosis. BRCA-mutated ovarian cancer often presents at an advanced stage, however, tend to have better response to platinum-based chemotherapy as compared with sporadic cases of epithelial ovarian cancer (EOC). In spite of this, most patients will develop a recurrence and eventually succumb to the disease. Preclinical studies are currently investigating natural compounds and their analogs for tumor-directed targets in ovarian cancer. The aim of this study is to investigate whether the STAT3 inhibitor HO-3867, a novel curcumin analog, has a therapeutic effect on BRCA1-mutated ovarian cancer. Our novel agent, HO-3867 and a commercial STAT3 inhibitor, STATTIC, significantly inhibited BRCA-mutated ovarian cancer cells in vitro in a dose- and time-dependent manner. BRCA-mutated ovarian cancer cells treated with HO-3867 exhibited a significant degree of apoptosis with elevated levels of cleaved caspase-3, caspase-7 and PARP. HO-3867 treatment induced more reactive oxygen species (ROS) in BRCA-mutated cells compared with wild-type cells, however, there was no increased ROS when benign ovarian surface epithelial cells were treated with HO-3867. BRCA1-mutated cancer cells had higher expression of Tyrosine-phosphorylated STAT3 (pTyr705) as compared with other STAT proteins. Furthermore, treatment of these cells with HO-3867 resulted in decreased expression of pTyr705 and its downstream targets cyclin D1, Bcl-2 and survivin. In addition, overexpression of STAT3 cDNA provided resistance to HO-3867-induced apoptosis. Our results show that HO-3867, a potent STAT3 inhibitor, may have a role as a biologically targeted agent for BRCA1-mutated cancers either as an adjunct to cytotoxic chemotherapy or as a single agent.
| Item Type: | Article |
|---|---|
| Subjects: | R Medicine / orvostudomány > RG Gynecology and obstetrics / nőgyógyászat, szülészet |
| Depositing User: | Dr. Tamás Kálai |
| Date Deposited: | 15 Jan 2015 11:31 |
| Last Modified: | 03 Apr 2023 08:23 |
| URI: | http://real.mtak.hu/id/eprint/20494 |
Available Versions of this Item
- HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. (deposited 15 Jan 2015 11:31) [Currently Displayed]
Actions (login required)
 |
Edit Item |
